Forte Biosciences (FBRX) ripped higher on Monday after the Dutch immunology giant, Argenx (ARGX), announced a definitive agreement to acquire it for $2.2 billion. The all-cash transaction is expected to close in the third quarter of 2026 and values FBRX shares at $77 each, representing a huge 40% upside on their previous close.
Following today’s gains, Forte Biosciences stock is trading at more than 3.5x its price at the start of this year.